MedPath

A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients

Phase 3
Completed
Conditions
Anemia
Registration Number
NCT00344409
Lead Sponsor
Kyowa Kirin Co., Ltd.
Brief Summary

To compare the effectiveness of KRN321 to placebo in the treatment of anemia in cancer patients receiving multi cycle platinum-containing chemotherapy

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria
  • patients diagnosed as lung or gynecological cancer
  • patients receiving platinum containing chemotherapy
  • written informed consent
  • hemoglobin concentration less than 11 d/dL at enrollment
  • life expectancy of more than 4 months
Exclusion Criteria
  • hemolysis, gastrointestinal bleeding, postoperative bleeding
  • iron deficiency
  • megaloblastic anemia
  • any primary hematological disorder that could cause anemia
  • received > 2 RBC transfusions with 4 weeks or any RBC transfusion within 2 weeks before randomization
  • prior treatment with KRN321
  • received erythropoetin therapy within 8 weeks before treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
To compare the proportion of subjects who reach red blood cell transfusion trigger
Secondary Outcome Measures
NameTimeMethod
To compare the effectiveness of KRN321 based on quality of life scores
To compare the effectiveness of KRN321 on the proportion of subjects achieving hemoglobin response
To compare the proportion of subjects who receive red blood cell transfusions

Trial Locations

Locations (7)

Shikoku region

🇯🇵

Ehime, Japan

Kyusyu region

🇯🇵

Fukuoka, Kagoshima, Japan

Chugoku region

🇯🇵

Hiroshima, Tottori, Japan

Tohoku region

🇯🇵

Iwate, Miyagi, Japan

Kinki region

🇯🇵

Nara, Osaka, Hyogo, Japan

Tokai region

🇯🇵

Shizuoka, Aichi, Japan

Kanto region

🇯🇵

Tokyo, Chiba, Ibaraki, Saitama, Niigata, Japan

© Copyright 2025. All Rights Reserved by MedPath